XMT 1522

Drug Profile

XMT 1522

Alternative Names: TAK 522; XMT1522

Latest Information Update: 23 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adimab; Mersana Therapeutics
  • Developer Mersana Therapeutics; Takeda
  • Class Antineoplastics; Auristatins; Immunoconjugates; Immunotoxins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Gastric cancer; Non-small cell lung cancer

Most Recent Events

  • 19 Jul 2018 The US FDA places partial clinical hold on phase I trial of XMT 1522
  • 04 Jun 2018 Interim efficacy, pharmacodyamics and adverse events data from a phase I trial in Breast cancer and Gastric cancer presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 14 May 2018 Mersana Therapeutics has patent protection in USA and foreign countries across its platforms and programmes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top